Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Third Quarter 2024 Pacira Biosciences Inc. Earnings Conference Call. At this time, all participants are listen only mode.
Pacira Biosciences Inc. (PCRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 1,978,997 | $29,783,905 | -5% | 0.04% |
| 2. | D E Shaw D. E. Shaw | 1,956,938 | $29,451,917 | +308% | 0.02% |
| 3. | Doma Perpetual Capital Management Pedro Escudero | 1,747,849 | $26,305,127 | +75% | 13.28% |
| 4. | 18,684,000 | $17,896,568 | 1.04% | ||
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,152,625 | $17,347,006 | +2059% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.25 | 1,512 | Director | 10,142 | 2024-08-16 | Filing | |
| $12.81 | 1,000 | Director | 17,552 | 2024-08-16 | Filing | |
| $12.90 | 2,000 | Director | 7,230 | 2024-08-14 | Filing | |
| $12.10 | 8,264 | Officer, Director | 107,784 | 2024-08-12 | Filing | |
| $12.01 | 3,400 | Director | 8,630 | 2024-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.86 | 500 | Officer | 115,700 | 2024-09-13 | Filing | |
| $20.05 | 945 | Officer | 94,307 | 2024-08-02 | Filing | |
| $28.25 | 2,836 | Officer | 95,557 | 2024-07-02 | Filing | |
| $28.72 | 3,970 | Officer | 38,075 | 2024-06-12 | Filing | |
| $28.57 | 5,012 | Officer | 44,569 | 2024-06-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,114,251 | $273,774,827 | 0% | |
| 2. | 5,098,424 | $172,020,826 | 0% | |
| 3. | 2,084,542 | $70,332,448 | 0.71% | |
| 4. | 1,936,158 | $65,325,971 | 0% | |
| 5. | 1,411,767 | $47,632,711 | 0.01% |
News See All
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2024 Earnings Call Transcript
Operator: Good day. And thank you for standing by. Welcome to the Q2 2024 Pacira BioSciences Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript
Pacira BioSciences, Inc. misses on earnings expectations. Reported EPS is $0.62 EPS, expectations were $0.64.
Aggressive Stock Portfolio: 13 Stocks Picked by Analysts
In this article, we will take a look at aggressive stock portfolio: 13 stocks picked by analysts.
5 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the five best small cap pharma stocks to invest in.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript
Pacira BioSciences, Inc. reports earnings inline with expectations. Reported EPS is $0.89 EPS, expectations were $0.89. Pacira BioSciences, Inc.
Hedge Funds are Betting on These 14 Sliding Stocks
Stocks jumped on December 6 after the release of yet another welcome data point for the Federal Reserve, showing the central bank’s consistent rate hikes in 2023 might finally be working.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Q3 2023 Pacira BioSciences Earnings Conference Call. At this time, all participants are in a listen-only mode.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Q2, 2023 Pacira BioSciences Inc. Earnings Conference Call. At this time, all participants are in listen-only mode.
5 Best Small Cap Pharma Stocks to Buy
In this piece, we will take a look at the five best small cap pharma stocks to buy.